This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: ISTH News

August ISTH Webinar: "TTP: New Insights in Pathogenesis and Treatment Modalities"

Thursday, July 31, 2014   (0 Comments)
Share |

Webinar registration is now open; register online today!

Date: August 27, 2014

Time: 17:00 - 18:00 GMT

*Check your time here.



Bernhard Lämmle, Center for Thrombosis and Hemostasis, University Medical Center, Mainz, Germany Spero Cataland, Ohio State University, Columbus, Ohio, USA

The objective of the next ISTH Academy webinar, titled, Thrombotic Thrombocytopenic Purpura (TTP): New Insights in Pathogenesis and Treatment Modalities, is to thoroughly cover how to treat patients with TTP along with the ways in which new molecular and biochemical discoveries could translate into new treatment options.

​The presentation will address the history of thrombotic thrombocytopenic purpura (TTP) and the discovery of the metalloprotease ADAMTS13 which plays a key role in regulating the size of multimeric von Willebrand factor. A severe deficiency of ADAMTS13, either hereditary or acquired due to inactivating autoantibodies, is an important pathogenetic factor for the onset of TTP. Some additional triggering mechanisms may be necessary to bring about acute disease both in hereditary as well as in autoantibody mediated ADAMTS13 deficiency.


After a brief discussion of the standard treatment, the presentation will address novel and emerging therapies for patients with acquired TTP and will include approaches to therapies currently being studied in clinical trials as well as novel approaches that may soon be entering clinical study. At the end of the presentation, participants will have a better understanding of these targeted approaches to therapy and their mechanisms of action. A better knowledge of these targeted therapies are essential going forward as they begin to play a greater role in the treatment of patients with acquired TTP.


>>Click for more information and vote on upcoming webinars!

Membership Management Software Powered by YourMembership  ::  Legal